Company intelligence / Profile preview
BioNTech SE
Mainz, Rhineland-Palatinate, Germanybiontech.com ↗
- Ownership
- Public · BNTX
- Employees
- ~6772
- Development stage
- Commercial
01
Overview
Successfully developed the first approved mRNA vaccine (COVID-19 vaccine Comirnaty with Pfizer). Has over 25 product candidates in clinical trials across oncology and infectious diseases. First colorectal cancer patient treated with individualized mRNA cancer vaccine in Phase 2 trial in 2021. Presented positive preliminary Phase 1/2 data for CAR-T program BNT211 in 2022.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- mRNA vaccinesmRNA cancer immunotherapiesnext-generation immunomodulatorstargeted cancer antibodiescell therapiesbispecific antibodiessmall molecules
- Industry
- Pharma
02
Drug pipeline
138 assets137 more assets in the full pipeline.
03
Partnerships
04
Financials
- Market cap
- $21.3B
- Total revenue
- $3.1B
- Enterprise value
- $10.3B
Beyond the preview
Go deeper on BioNTech SE.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioNTech SE.